“Right of appropriation (a) This clause applies to the extent that: (i) The Charged Property referred to in it constitutes Financial Collateral; and (ii) this Charge and the obligations of the Chargor under it constitute a Security Financial Collateral Arrangement (as defined in the Regulations). (b) The Chargee or any Receiver or Delegate may, by giving written notice to the Chargor upon, and at any time after, the date the Security created under this Charge has become enforceable, appropriate all or any Charged Property in and towards payment or discharge of the Security Liabilities, subject always to Regulation 18 of the Regulations. (c) The value of any Charged Property appropriated in accordance with this Clause shall be determined by the Chargees and, for this purpose, the parties agree that the value of any Charged Property shall be, in the case of any Shares, the market value of such Shares determined by the Chargee by reference to a public index or independent valuation or if neither such option is available or reasonably practicable given the then current circumstances, such other process as the Chargees may select; (d) The Chargor agrees that the method of valuation provided for in this Clause is commercially reasonable for the purposes of the Regulations …”
“Where a collateral-taker exercises a power contained in a security financial collateral arrangement to appropriate the financial collateral the collateral-taker must value the financial collateral in accordance with the terms of the arrangement and in any event in a commercially reasonable manner …”
“I have been instructed to consider the potential value of SGAH to Aapico. The valuation I have undertaken elsewhere in this report is at Market Value, i.e. assuming a willing buyer and willing seller. The potential value of SGAH to Aapico is not at Market Value, but would be at Investment Value, as defined in the IVS Framework (2017) as: ‘Investment Value is the value of an asset to a particular owner or prospective owner for individual investment or operational objectives. Investment Value is an entity-specific basis of value. Although the value of an asset to the owner may be the same as the amount that could be realised from its sale to another party, this basis of value reflects the benefits received by an entity from holding the asset and, therefore, does not involve a presumed exchange. Investment Value reflects the circumstances and financial objectives of the entity for which the valuation is being produced. It is often used for measuring investment performance’.”
“The value of SGAH to Aapico may therefore differ from what I have calculated as Market Value as it would be what is commonly known as ‘special purchaser’ value.”
“In my opinion there are two primary ways in which the value of a company to a special purchaser may differ from Market Value, these reflect: (a) Adjustments to the cash flows to reflect synergies and other strategic benefits to the special purchaser; and (b) Adjustments to valuation premia and discounts. 9.27 A special purchaser may seek to acquire a company because the synergies (cost savings, economies of scale, consolidation of key accounts) yield a value to the purchaser that is greater than the value achieved by other prospective investors and which will be reflected in a Market Value. I am unable to quantify what (if any) synergistic or strategic benefits there may be to Aapico from the acquisition of ABT’s 50.01% shareholding in SGAH from the information available. As a result, I am unable to propose an adjustment in this regard without that information. 9.28 As stated in section 8 above I apply a DLOM in my Market Value valuation of SGAH …”
“The DLOM reflects the principle that shareholdings in private companies are less liquid than those of quoted companies. This means that the shares are harder to sell which in turn suggests they would not attract the same value as quoted shares in an equivalent company. Investment value reflects the value of the shares to a specific purchaser and therefore the concept of marketability is disregarded and no DLOM should be applied …”
“In order to illustrate the potential investment value to Aapico (in line with my instructions) I include in the table below an adjusted valuation where I have removed the DLOM. For the avoidance of doubt this valuation does not reflect Market Value as is required by the Share Charge. It is not a comprehensive investment value valuation because as stated above I am unable to quantify the synergies to Aapico arising from the acquisition …”
“Further pursuant to Regulation 18(1) (which prevailed over the provisions of clause 9.3(c)) in circumstances where the Chargee appropriated the Security for its own use, a commercially reasonable valuation was required to take into account any special value of the shares to Aapico Investment or Aapico Hitech (or the applicable related party) in excess of the market value …”; and at para.20, to add the words “and 19A” so that it reads: “Alternatively, the Share Charge contained in implied term that any ‘independent valuation’ would have the characteristics identified in paragraphs 19 and 19A above …”
“The clause did not provide that the valuation should take account of the value of the Security to the Chargee as a special purchaser in circumstances where the Chargee proposed to appropriate the Security for its own use …”
“The market value of the Shares at15 August 2019 (excluding the loans made by made to SGAH by Aapico Investment) was US$92.5 million . The special purchaser value of the Shares to Aapico Investment and Aapico Hitech was in excess of this figure and was US$119.8 million or a figure in excess of US$92.5 million depending upon synergies arising from their acquisition of the Shares”
“The valuation did not have the characteristic pleaded at paragraph 19A above as it failed to account for the special value of the Shares to Aapico Investment and Aapico Hitech in excess of the market value of the Shares …”
“ATT submitted, with understandable circumspection, that, when regulation 18 specifies that ‘the collateral-taker must value the financial collateral in accordance with the terms of the arrangement and in any event in a commercially reasonable manner’, the concluding nine words could enable ÇH and ÇFI to require ATT to credit them with the premium, contrary to express terms of the charges. But, as Mr Milligan in effect accepted, ATT would be likely vigorously to resist any such suggestion. When ATT announced that it had appropriated the charged shares on27 April 2007 , it did so expressly on the basis that it would value them under clause 9.3 of the Charges. The Board need do no more than express scepticism that the concluding nine words of regulation 18 could over-ride this agreed basis …”
“I am unable to propose an adjustment in this regard without that information”
“It is not a comprehensive investment value valuation because … I am unable to quantify the synergies … arising from the acquisition …”
“i. Aapico’s intention for holding or selling the Shares and the shares in SGAH’s subsidiaries; ii. the extent of any entity-specific benefits to Aapico of holding the Shares, including synergies or other strategic benefits that would accrue to Aapico as a result of taking full ownership of SGAH; iii. any costs that Aapico would incur as a result of taking full ownership of SGAH; and iv. Aapico’s expectations at the valuation date for SAGUSA’s receivership and Oxy Capital’s enforcement of its rights in respect of Sakthi Portugal”
“reflects the benefits received by an entity from holding the asset.”